关于珀金埃尔默生命科学和体外诊断公司 珀金埃尔默生命科学与体外诊断公司将于2023年Q2更名，该公司提供端到端解决方案，帮助科学家、研究人员和临床医生更好地开展疾病诊断，发现新的个性化药物。 我们拥有11,000名专业人员，与商业、政府、学术及医疗健康领域的客户保持密切合作，为他们提供涵盖试剂、检测方法、仪器、自动化、信息化技术和战略服务的全面解决方案，助力客户加快工作流程，并带给其切实可行的洞见以作出更好的决策。 我们还通过极具活力的ESG (环境、社会及公司治理) 和可持续发展项目，致力于履行企业公民责任。公司2022年的收入约为33亿美元，服务于190个国家的客户，是标准普尔500指数的组成部分。 About The PerkinElmer Life Sciences and Diagnostics Company The PerkinElmer Life Sciences and Diagnostics company – which is to be renamed during the second quarter of 2023 – provides end-to-end solutions that help scientists, researchers and clinicians better diagnose disease and discover new and more personalized drugs. Its dedicated team of 11,000 collaborates closely with commercial, government, academic and healthcare customers to deliver reagents, assays, instruments, automation, informatics and strategic services that accelerate workflows, deliver actionable insights and support improved decision making. The Company is also deeply committed to good corporate citizenship through dynamic ESG and sustainability programs. The Company reported revenues of approximately $3.3 billion in 2022, serves customers in 190 countries, and is a component of the S&P 500 index.